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Background: The reasons patients with haematological malignancies die in hospital more often than those with
other cancers is the subject of much speculation. We examined variations in place of death by disease sub-type
and time from diagnosis to death, to identify groups of ‘at-risk’ patients.
Methods: The study is based in the United Kingdom within the infrastructure of the Haematological Malignancy Research
Network (HMRN), a large on-going population-based cohort including all patients newly diagnosed with haematological
malignancies in the north of England. Diagnostic, demographic, prognostic, treatment and outcome data are collected for
each patient and individuals are ‘flagged’ for death. This study includes all adults (≥18 years) diagnosed 1st September 2004
to 31st August 2010 (n = 10,325), focussing on those who died on/before 31st August 2012 (n = 4829).
Results: Most deaths occurred in hospital (65.9%), followed by home (15.6%), nursing home (11%) and hospice (7.5%) and
there was little variation by diagnostic sub-type overall. Differences in place of death were, however, observed by time from
diagnosis to death, and this was closely related to sub-type; 87.7% of deaths within a month of diagnosis happened in hos-
pital and these largely occurred in patients with acute myeloid leukaemia, diffuse large B-cell lymphoma and myeloma. Pa-
tients surviving longer, and particularly beyond 1 year, were less likely to die in hospital and this corresponded with an
increase in the proportion of home deaths.
Conclusions: Time from diagnosis to death was clearly a major determinant of place of death and many patients
that died within three months of diagnosis did so in hospital. This was closely related to disease sub-type, with
early deaths occurring most notable in the more aggressive diseases. This is likely to be due to a combination of
factors including acute presentation, rapid disease progression without transition to a palliative approach to care
and complications of treatment. Nonetheless, hospital deaths also occurred frequently in indolent diseases,
suggesting that other factors were likely to contribute to the large proportion of hospital deaths overall. More
evidence is needed to fully understand these complex cancers.
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Many studies report that, given the choice, most people
would prefer to die at home [1-3]. However, it is well
recognised that patients with haematological malignan-
cies are more likely to die in hospital than those with
other cancers or non-malignant diseases [4-6]. This has
particular implications for haematology patients, as it
means they may not be dying in their preferred place.* Correspondence: debra.howell@york.ac.uk
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stated.Within the United Kingdom (UK), the promotion of
quality care for people approaching the end of their lives
has been driven by the National Health Service (NHS)
National End of Life Care Programme (NEoLCP – parts
of which now exist within NHS Improving Quality).
One of the aims of the NEoLCP was to enable people to
die in their preferred place, where possible. In order to
achieve this, Advance Care Planning was encouraged
and the use of tools such as Preferred Priorities for
Care, a document held by individuals and stating theirLtd. This is an Open Access article distributed under the terms of the Creative
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would like to die [7-9].
Evidence that such initiatives are impacting on place
of death in the UK is starting to accumulate, with a re-
cent study of deaths between 2004 and 2010 reporting a
sustained trend towards an increasing proportion of home
deaths, with corresponding decreases in hospital deaths
in cancer patients [10]. This change has also occurred in
haematological malignancies, although the decrease in
hospital deaths is not as marked as for other cancers
[11,12]. Importantly, the UK’s National Cancer Intelligence
Network confirmed that the excess of hospital deaths for
patients with haematological cancers persisted throughout
2001–2009 (68% for haematological cancers versus 47% for
other cancers) [11].
There is a substantial literature examining place of
death across various disease groups; but whilst there is
speculation and anecdote regarding the reasons for the
excess of hospital deaths in patients with haematological
cancers, this has not previously been analysed by disease
sub-type or time from diagnosis to death. Haematological
malignancies account for one in ten of all cancers in the
developed world however [13,14], and so their effective
management is of particular importance not only to
patients, but also health service managers and com-
missioners, who may be funding end-of-life care in in-
appropriate, acute hospital settings. Further information
relating to the factors associated with hospital death will
promote understanding and highlight ‘at-risk’ groups of
patients who may benefit from early interventions to
enable them to die in their preferred place, where pos-
sible. The aim of this study was to examine place of
death in patients with haematological malignancies and
variations related to diagnostic sub-type and time from
diagnosis to death.
Methods
This study was conducted within the infrastructure
of the Haematological Malignancy Research Network
(www.hmrn.org), an on-going patient cohort in the
north of England, covering a population of 3.6 million that
is broadly representative of the UK as a whole [15,16].
Established in 2004, HMRN is a collaboration between
the clinical haematology network, researchers at the
University of York and the Haematological Malignancy
Diagnostic Service (www.hmds.info), which diagnoses
all haematological malignancies in the study area, cod-
ing to the latest WHO classification scheme, ICD-0-3
[17]. More than 2,000 patients are registered annually
and diagnostic, demographic, prognostic, treatment and
outcome data are routinely abstracted from their med-
ical records to clinical trial standards. All HMRN pa-
tients are ‘flagged’ for death via linkage to national data
sources. HMRN has full ethical approval and Section251 exemption to collect data for audit and research
purposes, in addition to statutory governance approvals.
The current study includes all adults (≥18 years) newly
diagnosed with a haematological malignancy between
1st September 2004 and 31st August 2010, who died on
or before 31st August 2012; thus giving a minimum
follow-up time of two years and a maximum of eight years.
In the UK, hospitals provide generalist and/or specialist
services to address a wide range of healthcare needs;
hospices specifically focus on the provision of palliative
and end-of-life care for people with life-limiting condi-
tions; and nursing homes are residential institutions
where healthcare is provided for people whose needs
prevent them from living independently in their own
homes. We examined the proportion of people dying in
each of these settings, as well as those dying in their
own home and examined differences by diagnostic sub-
type. Time-to-death was also explored within specific
time-intervals, ranging from less than one month to
greater than one year, and variations were examined by
place of death overall. Finally, time-to-death was ex-
plored by disease sub-type, specifically within the con-
text of the hospital deaths. Data analyses was carried
out in SAS version 9.3 [18] using standard descriptive
methods. Odds ratios and corresponding 95% confidence
intervals were estimated for hospital and non-hospital
deaths using logistic regression; these were adjusted for
age at diagnosis, sex and diagnosis. The likelihood Ratio
Test for trend was used to examine patterns over the
follow-up period.
Results
10,325 patients aged 18 years and over were diagnosed with
a haematological cancer between 1st September 2004
and 31st August 2010. The most common sub-types
were diffuse large B-cell lymphoma (n = 1604), myeloma
(n = 1399), chronic lymphocytic leukaemia (n = 1279) and
myeloproliferative neoplasms (n = 1187) (Table 1). The
median age at diagnosis was 70.9 years, reflecting the late
age of disease onset of most of these cancers; the excep-
tions being Hodgkin lymphoma (median age 44 years) and
acute lymphoblastic leukaemia (median age 47 years).
4829 (46.8%) of the 10,325 patients in the cohort died
on, or before, the 31st August 2012. As can be seen from
Table 1, which is ordered by the absolute number of
deaths, the sub-types with the greatest number of deaths
were myeloma (n = 887), diffuse large B-cell lymphoma
(n = 831), myelodysplastic syndromes (n = 595) and acute
myeloid leukaemia (n = 573). Across all diseases, the most
common place of death was hospital (65.9%), followed by
home (15.6%), nursing home (11%) and hospice (7.5%).
Some variation was seen in place of death by diagnosis,
with the highest proportion of hospital deaths overall
occurring in patients with Hodgkin lymphoma, chronic








N (% of those diagnosed) Hospital Home Nursing home Hospice
N (% of deaths) N (% of deaths) N (% of deaths) N (% of deaths)
Total 10325 70.9 4829 (46.8) 3183 (65.9) 753 (15.6) 532 (11.0) 361 (7.5)
Myeloma 1399 73.0 887 (63.4) 572 (64.5) 139 (15.7) 107 (12.0) 69 (7.8)
Diffuse large B-cell lymphoma 1604 70.4 831 (51.8) 535 (64.5) 122 (14.7) 94 (11.3) 80 (9.6)
Myelodysplastic syndromes 794 76.0 595 (74.9) 422 (70.9) 94 (15.8) 44 (7.4) 35 (5.9)
Acute myeloid leukaemia 722 71.1 573 (79.4) 413 (72.1) 81 (14.1) 41 (7.2) 38 (6.6)
Chronic lymphocytic leukaemia 1279 71.6 424 (33.2) 276 (65.1) 74 (17.5) 50 (11.8) 24 (5.6)
Myeloproliferative neoplasms 1187 71.2 283 (23.8) 161 (56.9) 50 (17.7) 53 (18.7) 19 (6.7)
Marginal zone lymphoma 625 72.2 229 (36.6) 141 (61.6) 28 (12.2) 42 (18.3) 18 (7.9)
Lymphoproliferative disorder NOS2 378 77.0 165 (43.7) 101 (61.2) 26 (15.8) 30 (18.2) 8 (4.8)
Follicular lymphoma 656 64.5 148 (22.6) 91 (61.5) 29 (19.6) 16 (10.8) 12 (8.1)
Hodgkin lymphoma 576 44.4 126 (21.9) 94 (74.6) 17 (13.5) 10 (7.9) 5 (4.0)
Mantle cell lymphoma 173 74.0 123 (71.1) 66 (53.7) 24 (19.5) 13 (10.6) 20 (16.2)
T-cell lymphoma 206 64.9 117 (56.8) 83 (70.9) 20 (17.1) 5 (4.3) 9 (7.7)
Chronic myelomonocytic leukaemia 127 77.4 89 (70.1) 64 (71.9) 16 (18.0) 7 (7.9) 2 (2.2)
Acute lymphoblastic leukaemia 112 47.5 77 (68.8) 53 (68.8) 10 (13.0) 4 (5.2) 10 (13.0)
Primary myelofibrosis 88 74.1 49 (55.7) 34 (69.4) 8 (16.3) 3 (6.1) 4 (8.2)
Chronic myeloid leukaemia 203 59.2 44 (21.7) 32 (72.7) 4 (9.1) 5 (11.4) 3 (6.8)
Burkitt lymphoma 53 57.6 30 (56.6) 21 (70.0) 5 (16.6) 2 (6.7) 2 (6.7)
T-cell leukaemia 80 74.7 30 (37.5) 19 (63.3) 4 (13.3) 5 (16.7) 2 (6.7)
Hairy cell leukaemia 63 65.5 9 (14.3) 5 (55.6) 2 (22.2) 1 (11.1) 1 (11.1)
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portion of hospital deaths was generally somewhat lower
in patients with myeloma and non-Hodgkin lymphoma.
Nursing home deaths were more common in those with
very indolent diseases such as myeloproliferative neo-
plasms, marginal zone lymphoma and lymphoprolifera-
tive disorders. Hospice deaths were relatively infrequent
across all haematological disease sub-types, but some-
what more common in mantle cell lymphoma and acute
lymphoblastic leukaemia. Home deaths occurred more
often in patients with follicular and mantle cell lymphomas.
Place of death varied with time from diagnosis to death
(Table 2), with the highest proportion of hospital deaths
(87.7%) occurring within the first month of diagnosis.
Accompanied by a gradual increase in home and hospice
deaths, the proportion of hospital deaths fell to 71.6%
between 1–3 months and then again to 61.7% between
3–6 months, remaining at around this level thereafter.
Overall (Table 3), the odds of a non-hospital death was
nearly three times greater if death occurred between
1–3 months after diagnosis compared to the first month
of diagnosis (Odds Ratio (OR) 2.83, 95% Confidence Inter-
val (95% CI) 2.12-3.78), increasing to almost five times
greater one-year after diagnosis (OR 4.91, 95% CI 3.85-
6.28). The likelihood of dying outside hospital increased
significantly over the full eight year period of observation
(OR 1.02, 95% CI 1.01-1.02, Likelihood Ratio Test forTable 2 Variation in place of death and diagnostic sub-type b
Total 0-1 month
N (%) N (%)
Total deaths 4829 (100) 676 (100)
Place of death (total deaths)
Hospital 3183 (65.9) 593 (87.7)
Home 753 (15.6) 42 (6.2)
Nursing home 532 (11.0) 23 (3.4)
Hospice 361 (7.5) 18 (2.7)
Disease sub-type (hospital deaths)1
Myeloma 572 (18.0) 77 (13.0)
Diffuse large B-cell lymphoma 535 (16.8) 182 (30.7)
Myelodysplastic syndrome 422 (13.2) 27 (4.5)
Acute myeloid leukaemia 413 (13.0) 151 (25.5)
Chronic lymphocytic leukaemia 276 (8.7) 29 (4.9)
Myeloproliferative neoplasms 161 (5.1) 15 (2.5)
Hodgkin lymphoma 94 (2.9) 16 (2.7)
Follicular lymphoma 91 (2.8) 7 (1.2)
Acute lymphoblastic leukaemia 53 (1.7) 8 (1.3)
Others 566 (17.8) 81 (13.7)
1Ordered by absolute number of hospital deaths.Trend P < 0.0001), and these associations remained after
adjusting for age at diagnosis, sex and diagnosis.
Among hospital deaths within the first month of diagno-
sis (early deaths), diffuse large B-cell lymphoma (30.7%),
acute myeloid leukaemia (25.5%), and myeloma (13.0%)
predominate (Table 2, Figure 1). The relative contribution
of the different sub-types changed over time; with mye-
loma accounting for one in five hospital deaths occurring
more than a year from diagnosis (20.6%), followed by
myelodysplastic syndromes (14.2%) and chronic lympho-
cytic leukaemia (13.6%).
Discussion
This study examined, for the first time, the relationship
between place of death and time from diagnosis to death
across distinct haematological malignancy sub-types.
Over the eight years 2004–12, around two-thirds of all
deaths within our cohort occurred in hospital, and this
proportion was similar across most sub-types. Time
from diagnosis to death was clearly a major determinant
of place of death and, in this respect, sub-type was
important. Almost 90% of patients dying within a month
of diagnosis did so in hospital and these early deaths
largely comprised patients with acute myeloid leukaemia,
diffuse large B-cell lymphoma and myeloma. Patients
surviving longer, and particularly beyond one year, were
less likely to die in hospital. Our overall proportion ofy time from diagnosis to death
Time from diagnosis to death
1-3 months 3-6 months 6 months-1 year 1 year +
N (%) N (%) N (%) N (%)
623 (100) 538 (100) 767 (100) 2225 (100)
446 (71.6) 332 (61.7) 494 (64.4) 1318 (59.2)
76 (12.2) 90 (16.7) 133 (17.3) 412 (18.5)
61 (9.8) 72 (13.4) 74 (9.6) 302 (13.6)
40 (6.4) 44 (8.2) 66 (8.6) 193 (8.7)
85 (19.1) 40 (12.1) 98 (19.8) 272 (20.6)
98 (22.0) 65 (19.6) 79 (16.0) 111 (8.4)
55 (12.3) 68 (20.5) 85 (17.2) 187 (14.2)
82 (18.4) 51 (15.3) 48 (9.7) 81 (6.1)
14 (3.1) 19 (5.7) 35 (7.1) 179 (13.6)
8 (1.8) 10 (3.0) 18 (3.6) 110 (8.3)
20 (4.5) 14 (4.2) 14 (2.8) 30 (2.3)
7 (1.6) 2 (0.6) 16 (3.2) 59 (4.5)
10 (2.2) 3 (0.9) 14 (2.8) 18 (1.4)
67 (15.0) 60 (18.1) 87 (17.6) 271 (20.6)
Table 3 Risk of hospital vs non-hospital death by time from diagnosis to death
Place of death OR (95% CI)1 Adjusted OR
(95% CI)1Total Hospital Non-hospital
Time from diagnosis to death: 4829 (100) 3183 (65.9) 1646 (34.1)
0-1 month 676 (100) 593 (87.7) 83 (12.3) 1 1
1-3 months 623 (100) 446 (71.6) 177 (28.4) 2.83 (2.12-3.78) 3.00 (2.24-4.01)
3-6 months 538 (100) 332 (61.7) 206 (38.3) 4.43 (3.32-5.91) 5.01 (3.74-6.71)
6 months – 1 year 767 (100) 494 (64.4) 273 (35.6) 3.95 (3.00-5.19) 4.59 (3.47-6.08)
1 year + 2225 (100) 1318 (59.2) 907 (40.8) 4.91 (3.85-6.28) 5.87 (4.53-7.60)
1Odds Ratios (OR) and corresponding 95% Confidence Intervals (95% CI) adjusted for age, sex and diagnosis.
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UK national data (68%) [11]; and previous studies have
also reported longer survival to be associated with deaths
outside hospital [6,19], although none have examined these
variables by specific haematological disease sub-type.
Emanating from within an established population-based
patient cohort [15,16], the findings from this study are ro-
bust and it is likely that the patterns we observed are
generalizable across the UK, and possibly to other coun-
tries with similar healthcare systems and cultural practices.
Centralised diagnostics is a core aspect of our cohort, and
all diagnoses are routinely coded by clinical staff to the lat-
est WHO scheme, currently ICD-0-3 [17]. Using these
data, we were able to examine place of death by specific
diagnostic sub-types, rather than adopting the more com-
mon approaches, in which these diseases have been exam-
ined either as part of the total group of cancer patients, as
a component of an ‘other’ category, or within combinations
of all, or certain haematological malignancies [20-25].
Importantly, this report has highlighted specific groups of
patients that are ‘at risk’ of hospital death. Haematological
diseases are complex, with heterogeneous pathways from
diagnosis to death. Patients with acute myeloid leukaemia,0



















Figure 1 Time from diagnosis to death by diagnostic sub-type (hospidiffuse large B-cell lymphoma and myeloma that die soon
after diagnosis are likely to die in hospital for a number of
reasons relating to their specific disease pathways. Acute
myeloid leukaemia, for example, is typically associated
with aggressive presentation and rapid progression. Ini-
tial hospital administered chemotherapy treatment can
cause severe toxicity, including neutropenic sepsis, and
there is a real possibility that sudden deterioration and
death could occur as a consequence of either disease pro-
gression or the side-effects of treatment. While diffuse
large B-cell lymphoma and myeloma may not always
present as acutely, and treatment is often administered
on an out-patient basis, it can be associated with simi-
lar toxicities to those seen with acute myeloid leukae-
mia. Such episodes may also result in hospital admissions,
which can have the propensity end with sudden, unex-
pected death.
Hospital deaths in this acute context, occurring rela-
tively unexpectedly and still within the framework of a
curative/life prolonging approach to care, are arguably
less avoidable than hospital deaths that occur after a lon-
ger illness. In the latter situation, where the disease has
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discuss the subject of preferred place of care and death,
and to make the appropriate arrangements. However,
our results show that large numbers of patients with in-
dolent diseases and longer survival also die in hospital,
indicating that additional factors also seem to contribute
to place of death.
One explanation, for this is that hospital may be the
preferred place of death for some, although this has
never previously been explored in patients with haem-
atological malignancies, despite differences in the trajec-
tories and treatment pathways of these diseases compared
to other illnesses. Patients may, however, be under the
care of the haematology team at the hospital over many
years [15], during which time they often have close and
sustained contact with the clinical team managing their
care, leading to strong mutual relationships. A further
issue to consider is that whilst we were able to identify
deaths that occurred in hospital as part of this study, it is
possible that some patients may have died in these
settings, but on palliative care wards or in General
Practitioner (GP) led local hospital wards, where the ap-
proach to care is palliative and similar to that of a hospice.
Other reasons for hospital deaths in patients with longer
survival include the remitting/relapsing course of many of
these diseases, which may result in treatments being given
(sometimes for symptomatic relief) in the later stages of
the pathway. The associated toxicities from this can again
result in sudden and unexpected death, without the time
to discuss place of death or plan home-discharge if this
is the preferred and feasible option. Importantly, there
is often a supportive element to the treatment of these
diseases, including the transfusion of blood products for
bone marrow failure and the administration of intraven-
ous antibiotics for infection, both of which are generally
delivered in an in-patient setting, and from which (par-
ticularly during the terminal stage of illness) the patient
may not recover, thus resulting in hospital death.
Furthermore, the complexities associated with the tra-
jectory of these diseases mean that identifying the transi-
tion from a curative to palliative approach to care can be
challenging. As a consequence, clinicians have been cri-
ticised for continuing to treat advanced disease that is
unlikely to respond to treatment, rather than recognising
that the transition should occur [26,27]. Further under-
standing of such transitions, as well as evidence to guide
both patient and clinician treatment decisions (including
quality of life, biological and economic data) would con-
tribute to early treatment/care planning and may lead to a
reduction in the number of hospital deaths.
Despite these difficulties increasing proportions of deaths
are occurring outside hospital in patients that survive lon-
ger. As well as facilitating a defined transition and advance
end-of-life care planning, longer survival is generallyassociated with an increased likelihood of receiving in-
put from specialist palliative care services, which is re-
ported to facilitate home deaths for people with both
haematological cancers and solid tumours [6,28-32]. It is
not always clear whether palliative care referrals are made
to facilitate home death when this is the preferred place,
or whether involvement of the palliative care team facil-
itates discussions about end-of-life care, and exploration
of the feasibility of home-death. The impact of such re-
ferrals is, however, clear and important.
Whilst we did not examine this in the present study,
one factor worth considering in future projects is the
impact of time-to-diagnosis on both survival and place
of death. It is recognised that the time interval between
symptom onset and diagnosis in patients with haemato-
logical malignancies, and especially myeloma and lymph-
oma, is often particularly prolonged [33-35]. Compared
to people with other cancers such patients are more likely
to present to hospital for the first time as an emergency,
which is itself associated with poorer survival [36]. De-
layed diagnosis is also reported to lead to increased com-
plications (such as anaemia, bone disease and renal failure
in myeloma) at diagnosis [37] possibly requiring hospital-
isation. In such circumstances, we would anticipate that
some of the patients experiencing protracted time-to-
diagnosis (especially those with myeloma and lymphoma)
are included in the group that die soon after diagnosis
and in hospital. Importantly, however, the situation is
far from straight-forward and no single explanation is
likely to fit all disease types; the early hospital deaths we
identified will undoubtedly also include patients that
experienced rapid symptom onset and diagnosis, par-
ticularly those with acute myeloid leukaemia.
Haematological malignancies are commoner in older
people, and patients with these diseases may also have
significant or multiple co-morbidities that contribute to
their death. Although we did not examine cause of death
within our study, the influence of comorbidities may be
important and could in fact have a greater influence on
place of death than the haematological malignancy itself;
and this is particularly so for patients with more indo-
lent disease sub-types. Whilst deaths from comorbidities
undoubtedly occur in all the locations we examined, it is
interesting to note the high proportion of nursing home
deaths in patients with diseases that are usually moni-
tored rather than actively treated, such as lymphoprolif-
erative disorders (median age at diagnosis 77 years). It is
likely that these patients are nursing home residents due
to other comorbid/age-related factors, rather than solely
because of their haematological malignancy.
Existing research has reported that home deaths are
more likely to occur when home is stated as the patient’s
preferred place of care [6]. Within this study, it was not
our intention to explore preferred place of care and
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have previously found great variation in the frequency
and methods of documentation of such conversations
[38]. Although standardised tools exist to facilitate dis-
cussion and documentation in primary care, we have not
generally observed the use of these in secondary care
settings; hand searching of hospital records for such in-
formation was beyond the scope of this present study.
Conclusions
In the UK, a large proportion of patients with haemato-
logical malignancies die in hospital across all diagnostic
sub-types. Time from diagnosis to death was clearly a major
determinant of place of death and many patients that
died within three months of diagnosis did so in hospital.
This was closely related to disease sub-type, with early
deaths occurring most notable in the more aggressive
diseases. This is likely to be due to a combination of fac-
tors including acute presentation, rapid disease progres-
sion without transition to a palliative approach to care
and complications of treatment. Nonetheless, hospital
deaths also occurred frequently in indolent diseases,
suggesting that other factors were likely to contribute to
the large proportion of hospital deaths overall. This may
include hospital being the preferred place of care, or in-
deed death being caused by comorbidities unrelated to the
haematological malignancy, but requiring hospitalisation.
More evidence is needed to fully understand these com-
plex cancers.
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